Evidence map›Paper›PMID 28120846›Full record

ArticleMucosal immunology2017

Cortactin deficiency causes increased RhoA/ROCK1-dependent actomyosin contractility, intestinal epithelial barrier dysfunction, and disproportionately severe DSS-induced colitis.

A F Citalán-Madrid, H Vargas-Robles, A García-Ponce, M Shibayama, A Betanzos, P Nava, C Salinas-Lara, K Rottner, R Mennigen, M Schnoor

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Mucosal immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Bamboo Shoot andCurrent issues in molecular biology · 2022
    Article
  9. Review
  10. Article
  11. Cortactin loss protects against hemin-induced acute lung injury in sickle cell disease.American journal of physiology. Lung cellular and molecular physiology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. CSE/HFrontiers in immunology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

A F Citalán-MadridDepartment of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.
H Vargas-RoblesDepartment of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.
A García-PonceDepartment of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.
M ShibayamaDepartment of Infectomics and Molecular Pathogenesis, CINVESTAV-IPN, Mexico City, Mexico.
A BetanzosDepartment of Infectomics and Molecular Pathogenesis, CINVESTAV-IPN, Mexico City, Mexico.
P NavaDepartment of Physiology, Biophysics and Neurosciences, CINVESTAV-IPN, Mexico City, Mexico.
C Salinas-LaraLaboratory of Histology and Pathology, Faculty of Superior Studies Iztacala, UNAM, Mexico City, Mexico.
K RottnerDivision of Molecular Cell Biology, Zoological Institute, TU Braunschweig, Braunschweig, Germany.
R MennigenClinic for General and Visceral Surgery, University Clinic of Münster, Münster, Germany.
M SchnoorDepartment of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.
Center for Research and Advanced Studies of the National Polytechnic Institute · MXConsejo Nacional de Humanidades, Ciencias y Tecnologías · MXTechnische Universität Braunschweig · DEUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intestinal epithelium constitutes a first line of defense of the innate immune system. Epithelial dysfunction is a hallmark of intestinal disorders such as inflammatory bowel diseases (IBDs). The actin cytoskeleton controls epithelial barrier integrity but the function of actin regulators such as cortactin is poorly understood. Given that cortactin controls endothelial permeability, we hypothesized that cortactin is also important for epithelial barrier regulation. We found increased permeability in the colon of cortactin-KO mice that was accompanied by reduced levels of ZO-1, claudin-1, and E-cadherin. By contrast, claudin-2 was upregulated. Cortactin deficiency increased RhoA/ROCK1-dependent actomyosin contractility, and inhibition of ROCK1 rescued the barrier defect. Interestingly, cortactin deficiency caused increased epithelial proliferation without affecting apoptosis. KO mice did not develop spontaneous colitis, but were more susceptible to dextran sulfate sodium colitis and showed severe colon tissue damage and edema formation. KO mice with colitis displayed strong mucus deposition and goblet cell depletion. In healthy human colon tissues, cortactin co-localized with ZO-1 at epithelial cell contacts. In IBDs patients, we observed decreased cortactin levels and loss of co-localization with ZO-1. Thus, cortactin is a master regulator of intestinal epithelial barrier integrity in vivo and could serve as a suitable target for pharmacological intervention in IBDs.

Indexed as

ActomyosinAnimalsApoptosisCell ProliferationColitisCortactinCytoskeletonDextran SulfateDisease Models, AnimalHumansImmunity, InnateInflammatory Bowel DiseasesIntestinal MucosaMaleMiceMice, Inbred C57BLActomyosinCortactinDextran SulfaterhoA GTP-Binding Proteinrho-Associated KinasesRock1 protein, mouseTJP1 protein, humanZonula Occludens-1 Protein

Identifiers

PMID28120846
OpenAlexW2581566333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.